Home > All


September 10, 2017 10:06
Five Prime Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 at ESMO 2017 Congress Objective response rate of 48% and six-month disease control rate of 81% in patients at or below the maximum tolerated dose level; progression free survival of 7.4 months SOUTH ...
World  World      Mesothelioma Cancer  Mesothelioma Cancer